Is Emergent Biosolutions Inc (EBS) Stock About to Get Hot Wednesday?

Overall market sentiment has been down on Emergent Biosolutions Inc (EBS) stock lately. EBS receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Emergent Biosolutions Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on EBS!

See Full EBS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With EBS Stock Today?

Emergent Biosolutions Inc (EBS) stock is trading at $2.18 as of 12:38 PM on Wednesday, Nov 29, a rise of $0.17, or 8.46% from the previous closing price of $2.01. The stock has traded between $2.00 and $2.36 so far today. Volume today is 1,048,489 compared to average volume of 1,342,386.

More About Emergent Biosolutions Inc

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. Click Here to get the full Stock Report for Emergent Biosolutions Inc stock.